Table 2.
Multivariate analysis for progression‐free and overall survival. CI, confidence interval; CN‐H/TP53abn, copy number‐high/TP53 abnormal; CN‐L/NSMP, copy number‐low/no specific molecular profile; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; MSI‐H, microsatellite instability‐high.
| Characteristic | Progression‐free survival | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| Age | 1.02 (1.00–1.03) | 0.029 | 1.04 (1.01–1.06) | 0.006 |
| Molecular subtype | ||||
| POLE/MSI‐H | – | < 0.001 | – | < 0.001 |
| CN‐L/NSMP | 1.01 (0.64–1.59) | 1.47 (0.64–3.38) | ||
| CN‐H/TP53abn | 2.86 (1.98–4.13) | 3.91 (1.94–7.86) | ||
| Stage (FIGO 2009) | ||||
| I/II | – | < 0.001 | – | < 0.001 |
| III | 3.96 (2.82–5.55) | 3.78 (2.07–6.90) | ||
| IV | 7.18 (5.09–10.1) | 7.86 (4.52–13.7) | ||
| ERBB2 status | ||||
| Wildtype | – | 0.52 | – | 0.69 |
| Mutated | 0.89 (0.33–2.43) | 0.54 (0.07–3.89) | ||
| Amplified | 1.28 (0.83–1.99) | 1.24 (0.60–2.56) | ||